SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLDX Celldex Therapeudics -- Ignore unavailable to you. Want to Upgrade?


To: Miljenko Zuanic who wrote (68)6/6/2020 11:35:08 AM
From: Miljenko Zuanic1 Recommendation

Recommended By
scaram(o)uche

  Respond to of 105
 
Next step would be 250 mg subcutaneous re-formulation for further studies.

For this task I would suggest strong dermatology oriented partner, with strong biologic reformulation capability.

Roche would be perfect, maybe even REGN would satisfy requirement!



To: Miljenko Zuanic who wrote (68)6/6/2020 1:25:21 PM
From: wood_ny  Read Replies (1) | Respond to of 105
 
Can CLDX get Rare Pediatric Disease Priority Review Voucher for Mast cell leukemia?